JXJing Xian

Jing Xian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing Xian has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Cuihong Chen

    MOE Key Laboratory of Pollution Processes and Environmental Criteria, College of Environmental Science and Engineering, Nankai University, Tianjin 300350, China

    1 shared publication
  • Fang Lian

    Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People’s Republic of China

    1 shared publication
  • Guining Liang

    Department of Physiology, School of Basic Medical Sciences Guangxi Medical University Nanning 530022 Guangxi China

    1 shared publication
  • Haijing Qin

    Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China

    1 shared publication
  • Hongqiao Wei

    School of Basic Medical Sciences, Guangxi Medical University, Nanning, China

    1 shared publication
  • Jie Zhang

    Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China

    1 shared publication

Latest Publications

  • The caveolin‐3 P104L mutation in LGMD‐1C patients inhibits non‐insulin‐stimulated glucose metabolism and growth but promotes myocyte proliferation

    by Lina Shang, Tingting Chen, Jing Xian, Yufeng Deng, Yiyuan Huang, Qiwei Zhao, Guining Liang, Zhifeng Liang, Fang Lian, Hongqiao Wei, et al.

    The caveolin‐3 (CAV3) protein is known to be specifically expressed in various myocytes, and skeletal muscle consumes most of the blood glucose as an energy source to maintain normal cell metabolism and function. The P104L mutation in the coding sequence of the human CAV3 gene leads to the autosomal dominant disease limb‐girdle muscular dystrophy type 1C (LGMD‐1C). We previously reported that C2C12 cells transiently transfected with the P104L CAV3 mutant exhibited decreased glucose uptake and glycogen synthesis after insulin stimulation. The present study aimed to examine whether the P104L mutation affects C2C12 cell glucose metabolism, growth and proliferation without insulin stimulation. C2C12 cells stably transfected with CAV3‐P104L were established, and biochemical assays, Western blotting and confocal microscopy were used to observe glucose metabolism as well as cell growth and proliferation and to determine the effect of the P104L mutation on the PI3K/Akt signaling pathway. Without insulin stimulation, C2C12 cells stably transfected with the P104L CAV3 mutant exhibited decreased glucose uptake and glycogen synthesis, decreased CAV3 expression and reduced localization of CAV3 and GLUT4 on the cell membrane. The P104L mutant significantly reduced the cell diameters, but accelerated cell proliferation. Akt phosphorylation was inhibited, and protein expression of GLUT4, p‐GSK3β and p‐p70s6K, which are molecules downstream of Akt, was significantly decreased. The CAV3‐P104L mutation inhibits glycometabolism and cell growth but accelerates C2C12 cell proliferation by reducing CAV3 protein expression and cell membrane localization, which may contribute to the pathogenesis of LGMD‐1C.


  • Open Access

    Effects of Irbesartan Pretreatment on Pancreatic β‐Cell Apoptosis in STZ‐Induced Acute Prediabetic Mice

    by Cuihong Chen, Li Li, Haijing Qin, Zhenxing Huang, Jing Xian, Jinwei Cai, Yingfen Qin, Jie Zhang, Xinghuan Liang

    The current study was performed to investigate the effects and potential effects of irbesartan pretreatment on pancreatic β‐cell apoptosis in a streptozotocin‐ (STZ‐) induced acute mouse model of prediabetes. Twenty‐four male BALB/C mice (18–22 g) were randomly divided into three groups: normal control group (NC, n = 6), STZ group (STZ, n = 8), and irbesartan + STZ group (IRB + STZ, n = 10). In the IRB + STZ group, mice were administered irbesartan (300 mg/kg per day) by gavage for one week. The STZ group and IRB + STZ group received STZ (80 mg/kg by intraperitoneal (IP) injection once). The NC group received normal saline (80 mg/kg by IP injection once). Fasting blood glucose prior to STZ injection and presacrifice was analysed using samples withdrawn from the caudal vein to confirm the induction of prediabetes. Haematoxylin and eosin staining, immunohistochemical detection of insulin, and apoptosis analysis were performed. Reverse transcription‐quantitative polymerase chain reaction was used to detect angiotensin II type 1 receptor (AT1R), caspase‐3, and p38 mitogen‐activated protein kinase (MAPK) mRNA expression. Blood glucose was significantly higher in the STZ group (9.01 ± 1.1089 vs 4.78 ± 0.7026) and IRB + STZ group (7.86 ± 1.1811 vs 4.78 ± 0.7026) compared with the NC group (P < 0.05). In comparison to the STZ group, the islet cell damage was marginally improved in the IRB + STZ group, and the IRB + STZ group had a significantly lower apoptotic rate than the STZ group (22.42 ± 8.3675 vs 50.86 ± 5.3395, P < 0.001). AT1R expression in the IRB + STZ group was lower than that in the STZ group (1.56 ± 1.2207 vs 3.92 ± 2.4392, P < 0.05). The mRNA expression of caspase‐3 in pancreatic tissue was significantly lower in the IRB + STZ group than in the STZ group (0.90 ± 0.7272 vs 1.88 ± 1.0572, P < 0.05). Similarly, the IRB + STZ group also had lower p38MAPK levels than the STZ group (1.16 ± 1.0642 vs 2.55 ± 1.7925, P > 0.05). In conclusion, irbesartan pretreatment improved glucose levels and insulin secretion and decreased islet β‐cell apoptosis to protect islet β cells in an STZ‐induced acute prediabetic mouse model.